Clinical Trial: Trial of XL092 in Combination with Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863311) titled 'Trial of XL092 in Combination with Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC' on March 03.

Brief Summary: The study population for this Phase 2 study will include men and women >= 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuo...